New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33 percent when the coronavirus swept across Europe.
TERAVOLT registry tracks outcomes among thoracic cancer patients sickened by COVID-19
